{
  "id": "58847e36e56acf5176000009",
  "type": "yesno",
  "question": "Is adalimumab effective for hidradenitis suppurativa?",
  "ideal_answer": "Yes, Adalimumab, a recombinant, fully humanized, anti-tumor necrosis factor alpha (anti-TNF-\u03b1) monoclonal antibody, is the only officially approved treatment for the management of moderate-to-severe hidradenitis suppurativa.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/25580790",
    "http://www.ncbi.nlm.nih.gov/pubmed/26470624",
    "http://www.ncbi.nlm.nih.gov/pubmed/26201313",
    "http://www.ncbi.nlm.nih.gov/pubmed/26831295",
    "http://www.ncbi.nlm.nih.gov/pubmed/18754844",
    "http://www.ncbi.nlm.nih.gov/pubmed/27665300",
    "http://www.ncbi.nlm.nih.gov/pubmed/23670060",
    "http://www.ncbi.nlm.nih.gov/pubmed/25040429",
    "http://www.ncbi.nlm.nih.gov/pubmed/21091684",
    "http://www.ncbi.nlm.nih.gov/pubmed/21756155",
    "http://www.ncbi.nlm.nih.gov/pubmed/24144253",
    "http://www.ncbi.nlm.nih.gov/pubmed/19997689",
    "http://www.ncbi.nlm.nih.gov/pubmed/26801356",
    "http://www.ncbi.nlm.nih.gov/pubmed/19371236",
    "http://www.ncbi.nlm.nih.gov/pubmed/20652119",
    "http://www.ncbi.nlm.nih.gov/pubmed/27799806",
    "http://www.ncbi.nlm.nih.gov/pubmed/23247938",
    "http://www.ncbi.nlm.nih.gov/pubmed/23106519",
    "http://www.ncbi.nlm.nih.gov/pubmed/20628295",
    "http://www.ncbi.nlm.nih.gov/pubmed/19213236",
    "http://www.ncbi.nlm.nih.gov/pubmed/22644772",
    "http://www.ncbi.nlm.nih.gov/pubmed/27136622",
    "http://www.ncbi.nlm.nih.gov/pubmed/22013960",
    "http://www.ncbi.nlm.nih.gov/pubmed/19451504",
    "http://www.ncbi.nlm.nih.gov/pubmed/21457202",
    "http://www.ncbi.nlm.nih.gov/pubmed/21128923",
    "http://www.ncbi.nlm.nih.gov/pubmed/27518661",
    "http://www.ncbi.nlm.nih.gov/pubmed/27388530"
  ],
  "snippets": [
    {
      "text": "If patient is not improved, then Adalimumab 160\u00a0mg at week 0, 80\u00a0mg at week 2; then 40\u00a0mg subcutaneously weekly should be administered (LOE Ib, SOR A). If improvement occurs then therapy should be maintained as long as HS lesions are present.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26831295",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Reduction in pain scores and improvement in depressive symptoms in patients with hidradenitis suppurativa treated with adalimumab in a phase 2, randomized, placebo-controlled trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27136622",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Adalimumab treatment for 16 weeks improved HS lesions significantly versus placebo\u00a0(NCT00918255).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27136622",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION: Patients with moderate to severe HS had a high degree of pain and depressive symptoms\u00a0at baseline. Adalimumabtherapy was associated with decreased pain and depressive symptoms compared to baseline.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27136622",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27799806",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Adalimumab, a recombinant, fully humanized, anti-tumor necrosis factor alpha (anti-TNF-\u03b1) monoclonal antibody, is the only officially approved treatment for the management of moderate-to-severe HS. Case reports, concerning 42 patients who received adalimumab for severe HS (with the standard dose regimen for psoriasis), reported a cumulative response rate of 58% (\u226550% in 23 patients) with a relapse rate of 71% (10 out of 14 patients). The most recent and most well-powered phase III, randomized placebo-controlled trials for the evaluation of the efficacy and safety of adalimumab in treatment of moderate-to-severe HS (PIONEER studies I and II) showed that the Hidradenitis Suppurativa Clinical Response (HiSCR) rate at week 12 was significantly higher for patients randomized to adalimumab compared to placebo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27799806",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In conclusion, adalimumab, to date, holds the most robust data regarding treatment efficacy in HS. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27799806",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Adalimumab (Humira) for the Treatment of Hidradenitis Suppurativa.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27388530",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Adalimumab (Humira\u00ae) is a novel therapy approved by the US Food and Drug Administration, Health Canada, and the European Commission for the treatment of hidradenitis suppurativa (HS).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27388530",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Taken together, these data conclude that treatment of HS with adalimumab is a safe and effective therapy resulting in a significant decrease in abscess and inflammatory nodule counts within the first 12 weeks of treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27388530",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21091684",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Hidradenitis suppurativa managed with adalimumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19213236",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19371236",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Long-term successful adalimumab therapy in severe hidradenitis suppurativa.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19451504",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21756155",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26201313",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Adalimumab in treatment-resistant hidradenitis suppurativa following recurrence after extensive affected area excision: a review of biologics therapy",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24144253",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Adalimumab (antitumour necrosis factor-\u03b1) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22013960",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19371236",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In a phase 2 trial, adalimumab, an antibody against tumor necrosis factor \u03b1, showed efficacy against hidradenitis suppurativa.PIONEER I and II were similarly designed, phase 3 multicenter trials of adalimumab for hidradenitis suppurativa, with two double-blind, placebo-controlled periods.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27518661",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here we report a case of a patient with severe recalcitrant hidradenitis suppurativa successfully treated with adalimumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19371236",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recent reports have demonstrated that adalimumab, a tumor necrosis factor (TNF) antagonist, may be effective in the treatment of patients with HS who have failed conventional therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19213236",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conclusion Adalimumab appears to be an effective and safe treatment for refractory HS.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19451504",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21091684",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Hidradenitis suppurativa managed with adalimumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19213236",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19371236",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27518661",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Adalimumab treatment for hidradenitis suppurativa associated with Crohn's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25580790",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Long-term successful adalimumab therapy in severe hidradenitis suppurativa.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19451504",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Conclusion Adalimumab appears to be an effective and safe treatment for refractory HS..",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19451504",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21756155",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Here we report a case of a patient with severe recalcitrant hidradenitis suppurativa successfully treated with adalimumab..",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19371236",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Adalimumab is suitable for the long-term treatment of hidradenitis suppurativa and presents a further conservative treatment approach..",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21091684",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26201313",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27799806",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [
    "http://www.disease-ontology.org/api/metadata/DOID:2280",
    "http://www.biosemantics.org/jochem#4002010",
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000068879",
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017497"
  ],
  "exact_answer": "Yes"
}